Biotech Values

[Bio_pete]

Is TEVA developing a pill form of Copaxone or was this just poor writing?

"Despite this, the main concern is the fact that the Copaxone patent, Teva's only branded drug, will expire in three years. The significance is a loss of revenue that could reach $3 billion a year beginning in 2014. Moreover, the regular Copaxone treatment (given by injection) will be replaced by a pill version over the next few years. At this stage, especially following Teva's failure to develop its drug, it appears that there are more popular "favorites" that could become leaders in the field, for example Novartis' Gilenya."

http://www.globes.co.il/serveen/globes/docview.asp?did=1000671036